FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 356:1304-1316 March 29, 2007 Number 13 Next

	Full Text PDF PDA Full Text PowerPoint Slide Set Supplementary Material Editorial by Tall, A. R. Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article PubMed Citation

ABSTRACT

Background Levels of high-density lipoprotein (HDL) cholesterol are inversely related to cardiovascular risk. Torcetrapib, a cholesteryl ester transfer protein (CETP) inhibitor, increases HDL cholesterol levels, but the functional effects associated with this mechanism remain uncertain.

Methods A total of 1188 patients with coronary disease underwent intravascular ultrasonography. After treatment with atorvastatin to reduce levels of low-density lipoprotein (LDL) cholesterol to less than 100 mg per deciliter (2.59 mmol per liter), patients were randomly assigned to receive either atorvastatin monotherapy or atorvastatin plus 60 mg of torcetrapib daily. After 24 months, disease progression was measured by repeated intravascular ultrasonography in 910 patients (77%).

Results After 24 months, as compared with atorvastatin monotherapy, the effect of torcetrapib–atorvastatin therapy was an approximate 61% relative increase in HDL cholesterol and a 20% relative decrease in LDL cholesterol, reaching a ratio of LDL cholesterol to HDL cholesterol of less than 1.0. Torcetrapib was also associated with an increase in systolic blood pressure of 4.6 mm Hg. The percent atheroma volume (the primary efficacy measure) increased by 0.19% in the atorvastatin-only group and by 0.12% in the torcetrapib–atorvastatin group (P=0.72). A secondary measure, the change in normalized atheroma volume, showed a small favorable effect for torcetrapib (P=0.02), but there was no significant difference in the change in atheroma volume for the most diseased vessel segment.

Conclusions The CETP inhibitor torcetrapib was associated with a substantial increase in HDL cholesterol and decrease in LDL cholesterol. It was also associated with an increase in blood pressure, and there was no significant decrease in the progression of coronary atherosclerosis. The lack of efficacy may be related to the mechanism of action of this drug class or to molecule-specific adverse effects. (ClinicalTrials.gov number, NCT00134173 [ClinicalTrials.gov] .)

Source Information

From the Cleveland Clinic, Cleveland (S.E.N., S.J.N., E.M.T.); Montreal Heart Institute, Montreal (J.-C.T.); Pfizer, New London, CT (J.H.R., C.L.S., W.T.D.); Instytut Kardiologii, Warsaw, Poland (W.R.); Pinnacle Health at Harrisburg Hospital, Harrisburg, PA (W.B.B.); and Tchefuncte Cardiovascular Associates, Covington, LA (G.P.L.).

This article (10.1056/NEJMoa070635) was published at www.nejm.org on March 26, 2007.

Address reprint requests to Dr. Nissen at the Department of Cardiovascular Medicine, Cleveland Clinic, 9500 Euclid Ave., Cleveland, OH 44195, or at nissens{at}ccf.org.

Full Text of this Article

This article has been cited by other articles:

• Funder, J. W. (2010). Aldosterone, Sodium, and Hypertension: Lessons From Torcetrapib?. Hypertension 55: 221-223 [Full Text]  
• Ritsch, A., Scharnagl, H., Eller, P., Tancevski, I., Duwensee, K., Demetz, E., Sandhofer, A., Boehm, B. O., Winkelmann, B. R., Patsch, J. R., Marz, W. (2010). Cholesteryl Ester Transfer Protein and Mortality in Patients Undergoing Coronary Angiography: The Ludwigshafen Risk and Cardiovascular Health Study. Circulation 121: 366-374 [Abstract] [Full Text]  
• van Schalkwijk, D. B., van Bochove, K., van Ommen, B., Freidig, A. P., van Someren, E. P., van der Greef, J., de Graaf, A. A. (2010). Developing computational model-based diagnostics to analyse clinical chemistry data. Brief Bioinform 0: bbp071v1-bbp071 [Abstract] [Full Text]  
• Sofat, R., Hingorani, A. D., Smeeth, L., Humphries, S. E., Talmud, P. J., Cooper, J., Shah, T., Sandhu, M. S., Ricketts, S. L., Boekholdt, S. M., Wareham, N., Khaw, K. T., Kumari, M., Kivimaki, M., Marmot, M., Asselbergs, F. W., van der Harst, P., Dullaart, R. P.F., Navis, G., van Veldhuisen, D. J., Van Gilst, W. H., Thompson, J. F., McCaskie, P., Palmer, L. J., Arca, M., Quagliarini, F., Gaudio, C., Cambien, F., Nicaud, V., Poirer, O., Gudnason, V., Isaacs, A., Witteman, J. C.M., van Duijn, C. M., Pencina, M., Vasan, R. S., D'Agostino, R. B. Sr, Ordovas, J., Li, T. Y., Kakko, S., Kauma, H., Savolainen, M. J., Kesaniemi, Y. A., Sandhofer, A., Paulweber, B., Sorli, J. V., Goto, A., Yokoyama, S., Okumura, K., Horne, B. D., Packard, C., Freeman, D., Ford, I., Sattar, N., McCormack, V., Lawlor, D. A., Ebrahim, S., Smith, G. D., Kastelein, J. J.P., Deanfield, J., Casas, J. P. (2010). Separating the Mechanism-Based and Off-Target Actions of Cholesteryl Ester Transfer Protein Inhibitors With CETP Gene Polymorphisms. Circulation 121: 52-62 [Abstract] [Full Text]  
• Sorrentino, S. A., Besler, C., Rohrer, L., Meyer, M., Heinrich, K., Bahlmann, F. H., Mueller, M., Horvath, T., Doerries, C., Heinemann, M., Flemmer, S., Markowski, A., Manes, C., Bahr, M. J., Haller, H., von Eckardstein, A., Drexler, H., Landmesser, U. (2010). Endothelial-Vasoprotective Effects of High-Density Lipoprotein Are Impaired in Patients With Type 2 Diabetes Mellitus but Are Improved After Extended-Release Niacin Therapy. Circulation 121: 110-122 [Abstract] [Full Text]  
• Chapman, M. J., Le Goff, W., Guerin, M., Kontush, A. (2010). Cholesteryl ester transfer protein: at the heart of the action of lipid-modulating therapy with statins, fibrates, niacin, and cholesteryl ester transfer protein inhibitors. Eur Heart J 31: 149-164 [Abstract] [Full Text]  
• Kahn, S. E., Haffner, S. M., Viberti, G., Herman, W. H., Lachin, J. M., Kravitz, B. G., Yu, D., Paul, G., Holman, R. R., Zinman, B., for A Diabetes Outcome Progression Trial (ADOPT) S, (2010). Rosiglitazone Decreases C-Reactive Protein to a Greater Extent Relative to Glyburide and Metformin Over 4 Years Despite Greater Weight Gain: Observations from A Diabetes Outcome Progression Trial (ADOPT). Diabetes Care 33: 177-183 [Abstract] [Full Text]  
• Wu, Z., Gogonea, V., Lee, X., Wagner, M. A., Li, X.-M., Huang, Y., Undurti, A., May, R. P., Haertlein, M., Moulin, M., Gutsche, I., Zaccai, G., DiDonato, J. A., Hazen, S. L. (2009). Double Superhelix Model of High Density Lipoprotein. J. Biol. Chem. 284: 36605-36619 [Abstract] [Full Text]  
• Vasan, R. S., Pencina, M. J., Robins, S. J., Zachariah, J. P., Kaur, G., D'Agostino, R. B., Ordovas, J. M. (2009). Association of Circulating Cholesteryl Ester Transfer Protein Activity With Incidence of Cardiovascular Disease in the Community. Circulation 120: 2414-2420 [Abstract] [Full Text]  
• Shah, P. K. (2009). The Yin and Yang of Cholesteryl Ester Transfer Protein in Cardiovascular Disease. Circulation 120: 2408-2410 [Full Text]  
• Cheung, A. K. (2009). Is Lipid Control Necessary in Hemodialysis Patients?. CJASN 4: S95-S101 [Abstract] [Full Text]  
• Lee, J. M.S., Robson, M. D., Yu, L.-M., Shirodaria, C. C., Cunnington, C., Kylintireas, I., Digby, J. E., Bannister, T., Handa, A., Wiesmann, F., Durrington, P. N., Channon, K. M., Neubauer, S., Choudhury, R. P. (2009). Effects of high-dose modified-release nicotinic Acid on atherosclerosis and vascular function a randomized, placebo-controlled, magnetic resonance imaging study.. J Am Coll Cardiol 54: 1787-1794 [Abstract] [Full Text]  
• Grover, S. A., Kaouache, M., Joseph, L., Barter, P., Davignon, J. (2009). Evaluating the Incremental Benefits of Raising High-Density Lipoprotein Cholesterol Levels During Lipid Therapy After Adjustment for the Reductions in Other Blood Lipid Levels. Arch Intern Med 169: 1775-1780 [Abstract] [Full Text]  
• Swirski, F. K., Weissleder, R., Pittet, M. J. (2009). Heterogeneous In Vivo Behavior of Monocyte Subsets in Atherosclerosis. Arterioscler. Thromb. Vasc. Bio. 29: 1424-1432 [Abstract] [Full Text]  
• Moreno, P. R., Sanz, J., Fuster, V. (2009). Promoting Mechanisms of Vascular Health: Circulating Progenitor Cells, Angiogenesis, and Reverse Cholesterol Transport. J Am Coll Cardiol 53: 2315-2323 [Abstract] [Full Text]  
• Funder, J. W. (2009). The Off-Target Effects of Torcetrapib. Endocrinology 150: 2024-2026 [Full Text]  
• Hu, X., Dietz, J. D., Xia, C., Knight, D. R., Loging, W. T., Smith, A. H., Yuan, H., Perry, D. A., Keiser, J. (2009). Torcetrapib Induces Aldosterone and Cortisol Production by an Intracellular Calcium-Mediated Mechanism Independently of Cholesteryl Ester Transfer Protein Inhibition. Endocrinology 150: 2211-2219 [Abstract] [Full Text]  
• Rye, K.-A., Bursill, C. A., Lambert, G., Tabet, F., Barter, P. J. (2009). The metabolism and anti-atherogenic properties of HDL. J. Lipid Res. 50: S195-S200 [Abstract] [Full Text]  
• Plump, A. S., Lum, P. Y. (2009). Genomics and cardiovascular drug development.. J Am Coll Cardiol 53: 1089-1100 [Abstract] [Full Text]  
• Chhatriwalla, A. K., Nicholls, S. J., Wang, T. H., Wolski, K., Sipahi, I., Crowe, T., Schoenhagen, P., Kapadia, S., Tuzcu, E. M., Nissen, S. E. (2009). Low levels of low-density lipoprotein cholesterol and blood pressure and progression of coronary atherosclerosis.. J Am Coll Cardiol 53: 1110-1115 [Abstract] [Full Text]  
• Tobis, J. M., Perlowski, A. (2009). Atheroma volume by intravascular ultrasound as a surrogate for clinical end points.. J Am Coll Cardiol 53: 1116-1118 [Full Text]  
• Briel, M., Ferreira-Gonzalez, I., You, J. J, Karanicolas, P. J, Akl, E. A, Wu, P., Blechacz, B., Bassler, D., Wei, X., Sharman, A., Whitt, I., Alves da Silva, S., Khalid, Z., Nordmann, A. J, Zhou, Q., Walter, S. D, Vale, N., Bhatnagar, N., O'Regan, C., Mills, E. J, Bucher, H. C, Montori, V. M, Guyatt, G. H (2009). Association between change in high density lipoprotein cholesterol and cardiovascular disease morbidity and mortality: systematic review and meta-regression analysis. BMJ 338: b92-b92 [Abstract] [Full Text]  
• Ghali, W. A, Rodondi, N. (2009). HDL cholesterol and cardiovascular risk. BMJ 338: a3065-a3065 [Full Text]  
• Kuula, H., Salo, T., Pirila, E., Tuomainen, A. M., Jauhiainen, M., Uitto, V.-J., Tjaderhane, L., Pussinen, P. J., Sorsa, T. (2009). Local and Systemic Responses in Matrix Metalloproteinase 8-Deficient Mice during Porphyromonas gingivalis-Induced Periodontitis. Infect. Immun. 77: 850-859 [Abstract] [Full Text]  
• Mackness, B., Mackness, M. (2009). High-density lipoprotein: why all the fuss?. Ann Clin Biochem 46: 5-7 [Abstract] [Full Text]  
• Pfeffer, M. A., Sacks, F. M. (2008). Leapfrogging Data: No Shortcuts for Safety or Efficacy Information. Circulation 118: 2491-2494 [Full Text]  
• Vergeer, M., Bots, M. L., van Leuven, S. I., Basart, D. C., Sijbrands, E. J., Evans, G. W., Grobbee, D. E., Visseren, F. L., Stalenhoef, A. F., Stroes, E. S., Kastelein, J. J.P. (2008). Cholesteryl Ester Transfer Protein Inhibitor Torcetrapib and Off-Target Toxicity: A Pooled Analysis of the Rating Atherosclerotic Disease Change by Imaging With a New CETP Inhibitor (RADIANCE) Trials. Circulation 118: 2515-2522 [Abstract] [Full Text]  
• Nicholls, S. J., Tuzcu, E. M., Brennan, D. M., Tardif, J.-C., Nissen, S. E. (2008). Cholesteryl Ester Transfer Protein Inhibition, High-Density Lipoprotein Raising, and Progression of Coronary Atherosclerosis: Insights From ILLUSTRATE (Investigation of Lipid Level Management Using Coronary Ultrasound to Assess Reduction of Atherosclerosis by CETP Inhibition and HDL Elevation). Circulation 118: 2506-2514 [Abstract] [Full Text]  
• Lange, R. A., Lindsey, M. L. (2008). HDL-cholesterol levels and cardiovascular risk: acCETPing the context. Eur Heart J 29: 2708-2709 [Full Text]  
• Seiler, S., Schlitt, A., Jiang, X.-C., Ulrich, C., Blankenberg, S., Lackner, K. J., Girndt, M., Werdan, K., Buerke, M., Fliser, D., Heine, G. H. (2008). Cholesteryl ester transfer protein activity and cardiovascular events in patients with chronic kidney disease stage V. Nephrol Dial Transplant 23: 3599-3604 [Abstract] [Full Text]  
• Hausenloy, D J, Yellon, D M (2008). Targeting residual cardiovascular risk: raising high-density lipoprotein cholesterol levels. Postgrad. Med. J. 84: 590-598 [Abstract] [Full Text]  
• Roe, M. T., Ou, F.-S., Alexander, K. P., Newby, L. K., Foody, J. M., Gibler, W. B., Boden, W. E., Ohman, E. M., Smith, S. C. Jr, Peterson, E. D. (2008). Patterns and prognostic implications of low high-density lipoprotein levels in patients with non-ST-segment elevation acute coronary syndromes. Eur Heart J 29: 2480-2488 [Abstract] [Full Text]  
• Hime, N. J., Black, A. S., Bulgrien, J. J., Curtiss, L. K. (2008). Leukocyte-derived hepatic lipase increases HDL and decreases en face aortic atherosclerosis in LDLr-/- mice expressing CETP. J. Lipid Res. 49: 2113-2123 [Abstract] [Full Text]  
• Su, Y. R., Blakemore, J. L., Zhang, Y., Linton, M. F., Fazio, S. (2008). Lentiviral Transduction of ApoAI Into Hematopoietic Progenitor Cells and Macrophages: Applications to Cell Therapy of Atherosclerosis. Arterioscler. Thromb. Vasc. Bio. 28: 1439-1446 [Abstract] [Full Text]  
• Laaksonen, R., Janis, M. T., Oresic, M. (2008). Lipidomics-Based Safety Biomarkers for Lipid-Lowering Treatments. ANGIOLOGY 59: 65S-68S [Abstract]  
• Nicholls, S. J., Tuzcu, E. M., Kalidindi, S., Wolski, K., Moon, K.-W., Sipahi, I., Schoenhagen, P., Nissen, S. E. (2008). Effect of Diabetes on Progression of Coronary Atherosclerosis and Arterial Remodeling: A Pooled Analysis of 5 Intravascular Ultrasound Trials. J Am Coll Cardiol 52: 255-262 [Abstract] [Full Text]  
• Mintz, G. S. (2008). Diabetic Coronary Artery Disease: How Little We Know and How Little Intravascular Ultrasound Has Taught Us. J Am Coll Cardiol 52: 263-265 [Full Text]  
• Krumholz, H. M., Lee, T. H. (2008). Redefining Quality -- Implications of Recent Clinical Trials. NEJM 358: 2537-2539 [Full Text]  
• deGoma, E. M., deGoma, R. L., Rader, D. J. (2008). Beyond high-density lipoprotein cholesterol levels evaluating high-density lipoprotein function as influenced by novel therapeutic approaches.. J Am Coll Cardiol 51: 2199-2211 [Abstract] [Full Text]  
• Frikke-Schmidt, R., Nordestgaard, B. G., Stene, M. C. A., Sethi, A. A., Remaley, A. T., Schnohr, P., Grande, P., Tybjaerg-Hansen, A. (2008). Association of Loss-of-Function Mutations in the ABCA1 Gene With High-Density Lipoprotein Cholesterol Levels and Risk of Ischemic Heart Disease. JAMA 299: 2524-2532 [Abstract] [Full Text]  
• Bloedon, L. T., Dunbar, R., Duffy, D., Pinell-Salles, P., Norris, R., DeGroot, B. J., Movva, R., Navab, M., Fogelman, A. M., Rader, D. J. (2008). Safety, pharmacokinetics, and pharmacodynamics of oral apoA-I mimetic peptide D-4F in high-risk cardiovascular patients. J. Lipid Res. 49: 1344-1352 [Abstract] [Full Text]  
• Wild, S., Byrne, C. D (2008). Time to rethink high-density lipoprotein?. Heart 94: 692-694 [Full Text]  
• Hausenloy, D J, Yellon, D M (2008). Targeting residual cardiovascular risk: raising high-density lipoprotein cholesterol levels. Heart 94: 706-714 [Abstract] [Full Text]  
• Ballantyne, C. M., Raichlen, J. S., Nicholls, S. J., Erbel, R., Tardif, J.-C., Brener, S. J., Cain, V. A., Nissen, S. E., for the ASTEROID Investigators, (2008). Effect of Rosuvastatin Therapy on Coronary Artery Stenoses Assessed by Quantitative Coronary Angiography: A Study to Evaluate the Effect of Rosuvastatin on Intravascular Ultrasound-Derived Coronary Atheroma Burden. Circulation 117: 2458-2466 [Abstract] [Full Text]  
• de Haan, W., de Vries-van der Weij, J., van der Hoorn, J. W.A., Gautier, T., van der Hoogt, C. C., Westerterp, M., Romijn, J. A., Jukema, J. W., Havekes, L. M., Princen, H. M.G., Rensen, P. C.N. (2008). Torcetrapib Does Not Reduce Atherosclerosis Beyond Atorvastatin and Induces More Proinflammatory Lesions Than Atorvastatin. Circulation 117: 2515-2522 [Abstract] [Full Text]  
• Movva, R., Rader, D. J. (2008). Laboratory Assessment of HDL Heterogeneity and Function. Clin. Chem. 54: 788-800 [Abstract] [Full Text]  
• Davidson, M., Meyer, P. M., Haffner, S., Feinstein, S., D'Agostino, R. Sr, Kondos, G. T., Perez, A., Chen, Z., Mazzone, T. (2008). Increased High-Density Lipoprotein Cholesterol Predicts the Pioglitazone-Mediated Reduction of Carotid Intima-Media Thickness Progression in Patients With Type 2 Diabetes Mellitus. Circulation 117: 2123-2130 [Abstract] [Full Text]  
• Nissen, S. E., Nicholls, S. J., Wolski, K., Nesto, R., Kupfer, S., Perez, A., Jure, H., De Larochelliere, R., Staniloae, C. S., Mavromatis, K., Saw, J., Hu, B., Lincoff, A. M., Tuzcu, E. M., for the PERISCOPE Investigators, (2008). Comparison of Pioglitazone vs Glimepiride on Progression of Coronary Atherosclerosis in Patients With Type 2 Diabetes: The PERISCOPE Randomized Controlled Trial. JAMA 299: 1561-1573 [Abstract] [Full Text]  
• Nissen, S. E., Nicholls, S. J., Wolski, K., Rodes-Cabau, J., Cannon, C. P., Deanfield, J. E., Despres, J.-P., Kastelein, J. J. P., Steinhubl, S. R., Kapadia, S., Yasin, M., Ruzyllo, W., Gaudin, C., Job, B., Hu, B., Bhatt, D. L., Lincoff, A. M., Tuzcu, E. M., for the STRADIVARIUS Investigators, (2008). Effect of Rimonabant on Progression of Atherosclerosis in Patients With Abdominal Obesity and Coronary Artery Disease: The STRADIVARIUS Randomized Controlled Trial. JAMA 299: 1547-1560 [Abstract] [Full Text]  
• Rumsfeld, J. S., Nallamothu, B. K. (2008). The Hope and Fear of Rimonabant. JAMA 299: 1601-1602 [Full Text]  
• Kastelein, J. J.P., de Groot, E. (2008). Ultrasound imaging techniques for the evaluation of cardiovascular therapies. Eur Heart J 29: 849-858 [Abstract] [Full Text]  
• Psaty, B. M., Lumley, T. (2008). Surrogate End Points and FDA Approval: A Tale of 2 Lipid-Altering Drugs. JAMA 299: 1474-1476 [Full Text]  
• Zernecke, A., Bernhagen, J., Weber, C. (2008). Macrophage Migration Inhibitory Factor in Cardiovascular Disease. Circulation 117: 1594-1602 [Abstract] [Full Text]  
• Ibanez, B., Vilahur, G., Cimmino, G., Speidl, W. S., Pinero, A., Choi, B. G., Zafar, M. U., Santos-Gallego, C. G., Krause, B., Badimon, L., Fuster, V., Badimon, J. J. (2008). Rapid change in plaque size, composition, and molecular footprint after recombinant apolipoprotein A-I Milano (ETC-216) administration: magnetic resonance imaging study in an experimental model of atherosclerosis.. J Am Coll Cardiol 51: 1104-1109 [Abstract] [Full Text]  
• Sanz, J., Moreno, P. R., Fuster, V. (2008). The year in atherothrombosis.. J Am Coll Cardiol 51: 944-955 [Full Text]  
• Tchoua, U., D'Souza, W., Mukhamedova, N., Blum, D., Niesor, E., Mizrahi, J., Maugeais, C., Sviridov, D. (2008). The effect of cholesteryl ester transfer protein overexpression and inhibition on reverse cholesterol transport. Cardiovasc Res 77: 732-739 [Abstract] [Full Text]  
• Levy, Y. (2008). High-density lipoprotein mass, cholesteryl ester transport protein, and macrophage reverse cholesterol transport: from the bedside back to the bench. Cardiovasc Res 77: 614-615 [Full Text]  
• van der Steeg, W. A., Holme, I., Boekholdt, S. M., Larsen, M. L., Lindahl, C., Stroes, E. S.G., Tikkanen, M. J., Wareham, N. J., Faergeman, O., Olsson, A. G., Pedersen, T. R., Khaw, K.-T., Kastelein, J. J.P. (2008). High-density lipoprotein cholesterol, high-density lipoprotein particle size, and apolipoprotein A-I: significance for cardiovascular risk: the IDEAL and EPIC-Norfolk studies.. J Am Coll Cardiol 51: 634-642 [Abstract] [Full Text]  
• Genest, J. (2008). The Yin and Yang of high-density lipoprotein cholesterol.. J Am Coll Cardiol 51: 643-644 [Full Text]  
• Yvan-Charvet, L., Pagler, T. A., Wang, N., Senokuchi, T., Brundert, M., Li, H., Rinninger, F., Tall, A. R. (2008). SR-BI inhibits ABCG1-stimulated net cholesterol efflux from cells to plasma HDL. J. Lipid Res. 49: 107-114 [Abstract] [Full Text]  
• Guerin, M., Le Goff, W., Duchene, E., Julia, Z., Nguyen, T., Thuren, T., Shear, C. L., Chapman, M. J. (2008). Inhibition of CETP by Torcetrapib Attenuates the Atherogenicity of Postprandial TG-Rich Lipoproteins in Type IIB Hyperlipidemia. Arterioscler. Thromb. Vasc. Bio. 28: 148-154 [Abstract] [Full Text]  
• Masoudi, F. A. (2007). Statins for Ischemic Systolic Heart Failure. NEJM 357: 2301-2304 [Full Text]  
• Rader, D. J. (2007). Illuminating HDL -- Is It Still a Viable Therapeutic Target?. NEJM 357: 2180-2183 [Full Text]  
• Barter, P. J., Caulfield, M., Eriksson, M., Grundy, S. M., Kastelein, J. J.P., Komajda, M., Lopez-Sendon, J., Mosca, L., Tardif, J.-C., Waters, D. D., Shear, C. L., Revkin, J. H., Buhr, K. A., Fisher, M. R., Tall, A. R., Brewer, B., the ILLUMINATE Investigators, (2007). Effects of Torcetrapib in Patients at High Risk for Coronary Events. NEJM 357: 2109-2122 [Abstract] [Full Text]  
• Zeller, M., Masson, D., Farnier, M., Lorgis, L., Deckert, V., Pais de Barros, J.-P., Desrumaux, C., Sicard, P., Grober, J., Blache, D., Gambert, P., Rochette, L., Cottin, Y., Lagrost, L. (2007). High Serum Cholesteryl Ester Transfer Rates and Small High-Density Lipoproteins Are Associated With Young Age in Patients With Acute Myocardial Infarction. J Am Coll Cardiol 50: 1948-1955 [Abstract] [Full Text]  
• Cuchel, M., Rader, D. J. (2007). Is the Cholesteryl Ester Transfer Protein Proatherogenic or Antiatherogenic in Humans?. J Am Coll Cardiol 50: 1956-1958 [Full Text]  
• Porchay-Balderelli, I., Pean, F., Bellili, N., Jaziri, R., Marre, M., Fumeron, F., for the DIABHYCAR Study Group, (2007). The CETP TaqIB Polymorphism Is Associated With the Risk of Sudden Death in Type 2 Diabetic Patients. Diabetes Care 30: 2863-2867 [Abstract] [Full Text]  
• Anantharamaiah, G. M., Mishra, V. K., Garber, D. W., Datta, G., Handattu, S. P., Palgunachari, M. N., Chaddha, M., Navab, M., Reddy, S. T., Segrest, J. P., Fogelman, A. M. (2007). Structural requirements for antioxidative and anti-inflammatory properties of apolipoprotein A-I mimetic peptides. J. Lipid Res. 48: 1915-1923 [Abstract] [Full Text]  
• Tuzcu, E. M., Starling, R. C., Thomas, J. D. (2007). Highlights of the 56th Annual Scientific Session of the American College of Cardiology, March 24-27, 2007. ACC.07 and i2 Summit Highlights: A Conversation With the Experts.. J Am Coll Cardiol 50: C2-31 [Full Text]  
• Singh, I. M., Shishehbor, M. H., Ansell, B. J. (2007). High-Density Lipoprotein as a Therapeutic Target: A Systematic Review. JAMA 298: 786-798 [Abstract] [Full Text]  
• (2007). Raising HDL Cholesterol in Patients With Diabetes. DOC News 4: 4-4 [Full Text]  
• Lehman, R. (2007). Evidently.... Evid. Based Med. 12: 103-103 [Full Text]  
• Nieland, T. J. F., Shaw, J. T., Jaipuri, F. A., Maliga, Z., Duffner, J. L., Koehler, A. N., Krieger, M. (2007). Influence of HDL-cholesterol-elevating drugs on the in vitro activity of the HDL receptor SR-BI. J. Lipid Res. 48: 1832-1845 [Abstract] [Full Text]  
• Lindsay, A. (2007). JournalScan. Heart 93: 1008-1010 [Full Text]  
• Authors/Task Force Members, , Bassand, J.-P., Hamm, C. W., Ardissino, D., Boersma, E., Budaj, A., Fernandez-Aviles, F., Fox, K. A.A., Hasdai, D., Ohman, E. M., Wallentin, L., Wijns, W., ESC Committee for Practice Guidelines (CPG), , Vahanian, A., Camm, J., De Caterina, R., Dean, V., Dickstein, K., Filippatos, G., Kristensen, S. D., Widimsky, P., McGregor, K., Sechtem, U., Tendera, M., Hellemans, I., Gomez, J. L. Z., Silber, S., Funck-Brentano, C., Document Reviewers, , Kristensen, S. D., Andreotti, F., Benzer, W., Bertrand, M., Betriu, A., De Caterina, R., DeSutter, J., Falk, V., Ortiz, A. F., Gitt, A., Hasin, Y., Huber, K., Kornowski, R., Lopez-Sendon, J., Morais, J., Nordrehaug, J. E., Silber, S., Steg, P. G., Thygesen, K., Tubaro, M., Turpie, A. G.G., Verheugt, F., Windecker, S. (2007). Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes: The Task Force for the Diagnosis and Treatment of Non-ST-Segment Elevation Acute Coronary Syndromes of the European Society of Cardiology. Eur Heart J 28: 1598-1660 [Full Text]  
• Psaty, B. M., Furberg, C. D. (2007). Rosiglitazone and Cardiovascular Risk. NEJM 356: 2522-2524 [Full Text]